Aclarion Inc. (Nasdaq: ACON, ACONW), a health care technology company based in Broomfield, has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, La., expanding access to its Nociscan solution. This collaboration allows SIL, a center known for its innovative treatment of chronic low back pain, to use Nociscan as part of its offerings.
“SIL has a long tradition of adopting innovative and less invasive techniques to treat patients suffering from chronic low back pain and Nociscan is a natural extension of this commitment,” said Dr. Pierce Nunley, orthopedic surgeon at SIL. “It’s often difficult to pinpoint the true source of chronic low back pain. The clinical evidence supporting Nociscan highlights the important role it plays as a decision support tool and a new hope for those who struggle with persistent back pain.”
The addition of SIL brings the total number of commercial centers utilizing Nociscan to 17, spanning eight states and four countries. “Dr. Nunley and his SIL colleagues are true leaders in the spine industry, and we are pleased they will begin using Nociscan to advance their understanding of low back pain and personalized treatment options for patients,” said Brent Ness, CEO of Aclarion.
Aclarion’s Nociscan is designed to help physicians identify the source of chronic low back pain by quantifying chemical biomarkers that indicate disc pain, showcasing a surgical success rate of 97% for treated pain-positive discs. The platform aims to provide valuable insights when used alongside other diagnostic tools.
